US Edition
TriMas: Q2 Earnings Snapshot
- Revvity released its Q2 2025 results with a loss of 34 cents per share, according to the company's report.
- Growth in the Signals software business was notable, with organic growth above 20% in Q2 FY2025, while Life Sciences revenue reached a new high, Revvity said.
- Revvity management realigned manufacturing, launched T-SPOT TB test automation after US approval, and introduced Signals One to mitigate a $135 million tariff headwind.
- Following the earnings release, Revvity management raised its revenue guidance for FY2025 to $2.84 billion to $2.88 billion and trimmed its EPS forecast to $4.85 to $4.95.
- Revvity management signaled confidence, noting GAAP revenue of $1.04 billion surpassed Wall Street's estimate, with no major deals needed for growth.
Insights by Ground AI
Does this summary seem wrong?
20 Articles
20 Articles
Coverage Details
Total News Sources20
Leaning Left7Leaning Right2Center8Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 41%
C 47%
12%
Factuality
To view factuality data please Upgrade to Premium
